Microvascular surgery has emerged as an attractive area for recent advances in the field of gene therapy. The present study investigated the survival of ischemic, experimental skin flaps after treatment with the gene encoding vascular endothelial growth factor (VEGF). In 30 Sprague-Dawley rats, anterior abdominal skin flaps supplied by the epigastric artery and vein were created. Ten animals were treated with a mixture of liposomes and the cDNA encoding the 121-amino acid isoform of VEGF. Another 10 animals were treated with control plasmid DNA and liposome transfection medium; a third group of 10 animals was given physiologic saline. Each solution was injected directly into the femoral artery distal to the origin of the epigastric pedicle supplying the flap. Four days after injection, the pedicle was ligated and blood flow in the flap was approximated using dye fluorescence. Seven days later, the amount of viable tissue within the flap was measured by planimetry. After the animals were killed, specimens from both the operated and nonoperated sides of the abdomen were harvested for
immunohistologic evidence of VEGF protein expression. Average dye fluorescence indices of the three groups (VEGF cDNA, control plasmid, and saline) 2 hours after pedicle ligation were 35.9, 23.9, and 53.9 percent, respectively (p < 0.05). Compared with the two control groups, flaps receiving VEGF cDNA had significantly greater tissue viability at the end of 7 days: 93.9 versus 28.1 percent for the control plasmid DNA group and 31.9 percent for the saline group (p < 0.05). Immunohistochemical staining documented increased deposition of VEGF protein in flaps that were infused with the VEGF cDNA versus saline alone (p < 0.05). The results indicated that the survival of ischemic tissues can be enhanced by administration of a cDNA encoding VEGF, a protein known to be important in the process of angiogenesis and wound healing.
In recent years, the microvascular system has emerged as an attractive area for advances in the field of gene therapy.1 Genetic sequences encoding angiogenic proteins have been delivered to tissues with the hope of improving wound healing.2 Augmentation of wound healing and, more specifically, increasing dermal angiogenesis in ischemic tissues could allow surgeons to create larger flaps based on a given vascular pedicle.
Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis. The treatment of ischemic tissues with VEGF protein has been the subject of extensive recent investigation. Padubidri et al. 3 injected the VEGF protein into the epigastric pedicle supplying large, bilateral abdominal island skin flaps. These flaps were then rendered ischemic for 10 minutes and observed for a period of 7 days. Compared with control animals, flaps treated with the VEGF protein had significantly increased tissue survival. Although the results were promising, the effects could be transient because of the short half-life of the protein in plasma. In our study, experimental ischemic flaps were treated with the cDNA encoding the VEGF protein in an attempt to promote angiogenesis and enhance graft survival. Using liposomes to improve the transfection efficacy of our therapeutic plasmid, we were able to demonstrate enhanced graft survival, and histologic evidence of increased angiogenesis, in VEGF-treated animals.
Materials and Methods

Plasmid Preparation
The cDNA encoding the 121-residue form of VEGF was obtained from Scios Nova, Inc. (Mountain View, Calif., courtesy of Judith Abraham, Ph.D.). Using the HindIII and KpnI restriction sites, this cDNA was cloned into the multiple cloning site of adeno-associated virus plasmid vector denoted MCS (courtesy of Mary Klotman, M.D., Mount Sinai Medical Center) to yield pCS-121. pAAV-MCS, is a recombinant adeno-associated virus expression cassette constructed from the adeno-associated virus-2 viral genome containing p201 vector as described by Samulski.4 pCS-121 contains the selectable gene conferring hygomycin resistance under the thymidine kinase promotor; the cytomegalovirus promotor drives transcription of the VEGF cDNA.
The efficacy of subsequent transfection in host cells was improved with the addition of Lipofectamine reagent (Bethesda Research Laboratories, Gaithersburg, Md.), a liposome formulation of the polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminiumtrifluoroacetate (DOPSA). A concentration of 2 µg/µl of the Lipofectamine reagent was used with Opti-Mem buffer (Gibco, Grand Island, N.Y.). One milliliter of the final infusate contained 14 µg plasmid DNA, 28 µg Lipofectamine, and 966 µl buffer.
Experimental Protocol
Three groups of 10 female Sprague-Dawley rats weighing 250 to 300 g each were used in the study. The animals were anesthetized with a mixture of intramuscular ketamine hydrochloride (30 mg/kg) and xylazine hydrochloride (12 mg/kg). After depilation of the lower abdominal skin with an alkali cream (Nair, Carter-Wallace, Cranberry, N.J.), the skin was prepared with aqueous Betadine (Purdue-Frederick Co., Norwalk, Conn.). Right-sided axial pattern skin flaps measuring 6 cm by 3 cm, based on the epigastric artery, were elevated under direct microscopic vision (Carl Zeiss, Inc., Oberkochen, Germany). After dissection of the femoral and epigastric vessels, the proximal and distal segments of the femoral artery and vein were isolated from the systemic circulation using microclamps (ABB-22V, ASSI, Westbury, N.Y.). Therapeutic or control solutions were delivered via a 30-gauge needle inserted into the femoral artery distal to the origin of the epigastric artery. Before delivery of either solution, 0.5 ml of saline was used to wash residual blood from the flap. All solutions were allowed to incubate within the flap for a period of 10 minutes. The first group, consisting of 10 animals, was given 0.5 ml of a solution containing the cDNA encoding VEGF packaged into the viral vector and suspended in the lipid transfection medium. A second group of 10 animals (group 2) was given the lipid medium containing the adeno-associated virus-viral vector without the VEGF gene insert, and a third group of 10 animals (group 3) was given physiologic saline alone. The arteriotomy created by the infusion needle was closed transversely with a single 11-0 nylon suture. After blood flow was returned, the flaps were resutured into place with 3-0 silk suture (Ethicon, Somerville, N.J.). Four days after creation of the flap, the pedicle was ligated under direct microscopic vision with a single 9-0 nylon ligature suture (Ethicon).
Ten minutes after ligation of the pedicle, background fluorescence was measured at four sites in each subject: (1) superior one-third of the flap, (2) middle one-third of the flap, (3) inferior one-third of the flap, and (4) medial to the superior portion of the flap, which was used as a reference point. A bolus of 0.5 ml fluorescein solution was then administered to each animal intraperitoneally. Two hours after ligation of the pedicle, dye fluorescence uptake at each of the four sites was measured with a perfusion fluorometer (Diversatronics, Brommall, Pa.), and recorded as the dye fluorescence index: (Equation)
Equation 1 Seven days after ligation of the pedicle, the percentage of cutaneous viability of the flap was measured by planimetry. The surface area of each abdominal skin flap and the respective area(s) of necrosis were traced onto an acetate grid, and the percentage of viable tissue was calculated as a percentage of the total surface area of the flap. The animals were then killed, the pedicles examined under the microscope, and the flaps submitted for immunohistochemical analysis.
Immunohistochemical Analysis
Tissue samples for pathologic examination were harvested at the time of death from both the operated and nonoperated sides of the abdomen in each of the three experimental groups. All specimens were preserved in 10% formalin solution before staining. The tissue samples were first stained with hematoxylin and eosin to determine the effect of delivery of the gene at the microscopic level. Each slide was examined using a standard light microscope at a power of 10×, and a standard grid was placed within the eyepiece of the microscope. The area displaying the most impressive vascularity during wound healing was noted just beneath a layer of muscle referred to in the rodent as the panniculus carnosus. Within this area, 10 consecutive grids in each specimen were examined for vessel number and size.
To evaluate the expression of VEGF in the flaps, the specimens were submitted for immunohistochemical staining. Formalin-fixed, paraffin-embedded tissue samples were deparaffinized and pretreated with 10 mM citric acid/buffer (pH, 6.0) at 95°C for 15 minutes for antigen retrieval. Monoclonal antibody to VEGF (R & D Systems, Minneapolis, Minn.) at a dilution of 1:100 was applied to the slides, which were then incubated for 2 hours at 37°C. Specimens of breast carcinoma known to stain for the VEGF protein were used as positive controls.
For each slide, 10 random high power fields at 40× were examined by two separate, blinded observers for the degree of antibody staining noted within the field and graded on a scale of 0 to 2 (0 = no staining noted, 1 = fine granular staining within the endothelial cytoplasm, and 2 = linear deposition of stain within the endothelial cytoplasm). The slides were compared with corresponding hematoxylin-and-eosin stained slides to confirm either the presence or absence of vessel lumina. All grades were made by the observers who were blinded to the nature of each slide. Grades were given based on the highest staining lumen present within each high powered field. When lumina seemed to belong to a single vessel, they were counted as such. Areas that might represent nonspecific chromogen deposition (i.e., tissue edges and adjacent tissue folding) were not considered in the results.
Statistical Analysis
Comparisons between the three experimental groups were made using a oneway analysis of variance. All data were analyzed using a standard statistical software program (CSS: Statistica for Windows, StatSoft, Inc., Tulsa, Okla., 1991), and all differences were considered significant at the p < 0.05 level.
Results
The results of dye fluorescence and ultimate surface viability are summarized in Figures 1 and 2 . Dye fluorescence index values 2 hours postligation were 35.9 percent for group 1 (gene-treated), 23.9 percent for group 2 (vector control), and 53.9 percent for group 3 (saline control). The absolute differences in fluorescence noted among the three groups was shown to be statistically significant (p < 0.05). More important, however, was the actual difference in the amount of viable tissue noted between the three groups at the end of 7 days. The mean amount of surviving tissue was 93.9 percent for group 1, 28.1 percent for group 2, and 31.9 percent for group 3 (p < 0.05). Eight of the flaps that received VEGF cDNA had 100-percent survival; two had less than 100-percent survival. Of those flaps that received either saline or vector, there was only a single flap from each group that displayed 100-percent survival. 
Immunohistochemical Analysis
The flaps of animals that received the VEGF cDNA had noticeable differences when examined under the light microscope. When stained with hematoxylin and eosin stains, those animals showed (1) an increased vascularity and (2) a smaller average vessel size (Fig. 3, above) when compared with saline-treated flaps (Fig. 3, below) . The average (mean) number of vessels observed in several given fields was 103.3 for the VEGF gene-treated specimens as compared with 93.0 for saline-treated specimens (p was not significant). A significant difference was seen when comparing the average size of the vessels seen beneath the panniculus carnosus. The average diameter of vessels in the VEGF gene-treated group was 20.5 µm, as compared with 35.1 µm for the saline-treated group (p < 0.05). Specimens from the vectortreated group had an average number of 91.6 vessels, with an average diameter of 31.4 µm ( Table I) . 
TABLE I Comparison of Mean Number of Vessels Identified and Mean
Lumen Diameter from Operated and Nonoperated Specimens from Saline, Vector, and VEGF Gene Groups (One-Way ANOVA)
Immunohistochemical staining for VEGF using antibodies directed against the protein detected VEGF deposition on endothelial cells. In gene-treated flaps, a band of stained antigen-antibody complexes surrounded the vessel lumen (Fig.  4, above) . Similar deposition was not seen in saline-treated flaps (Fig. 4, below) . Operated specimens that received the VEGF gene had an average endothelial cell staining grade of 1.20 as compared with similar saline-treated specimens that had an average grade of 0.30 (p < 0.05). In nonoperated specimens, the grades were 0.27 for the VEGF gene-treated group and 0.48 for the salinetreated group (p was not significant). No statistical difference was noted when the results of the individual observers were compared (Table II) . 
Discussion
Wounding begins with the disruption of blood vessels and local hemorrhage into the surrounding extravascular space. The resulting release of plasma proteins, most notably fibrinogen, and the accumulation of an extracellular gel provide a milieu into which components of mature stroma are deposited. Once triggered, the vessels remain in a hyperpermeable state and continue to leak even beyond the time of the initial hemorrhage. The hypoxic milieu created by the injury serves as a stimulus for the release of a multitude of growth factors that serve to repair the wounded tissue. In addition, cells such as keratinocytes, fibroblasts, and leukocytes are attracted to the wound margins as a barrier against water loss and bacterial invasion.
Angiogenesis plays an integral role in the process of wound healing. It involves a variety of cells and a host of specific and nonspecific growth factors. VEGF is one of the most interesting of these factors. It is a potent cell-specific cytokine, the predominant action of which is to promote angiogenesis. The cyclical creation and destruction of the uterine lining in preparation for implantation of the fertilized ovum and the complex process of wound healing involve VEGF. VEGF was initially identified as a protein secreted by tumor cells, which increased the permeability of local vessels to circulating macromolecules.5 It was subsequently shown to play a large role in embryogenesis, and more specifically, angiogenesis. VEGF is produced by a number of different cells of the body, but acts specifically on endothelial cells.6-9 Its importance in embryogenesis has been demonstrated in the mouse, where loss of a single allele between days 11 and 12 is uniformly lethal.10
The gene for VEGF has recently been mapped to a 15-kilobase region on chromosome 6p12.11 It is a relatively small region, but it shares significant homology with a multitude of genetic sequences encoding similar growth factors, including platelet-derived growth factor and human placenta growth factor. The importance of VEGF is highlighted by the fact that it is highly conserved among different species. Human VEGF shares up to 95-percent homology with bovine VEGF, for example. 8 Other angiogenic molecules that act in concert with VEGF include fibroblast growth factor and transforming growth factor-beta. The actions of VEGF are numerous. The molecule increases endothelial cell permeability, growth, and migration,12 and directs the expression of other endothelial cell genes to produce proteases that digest components of the extracellular matrix that impede angiogenesis.13 Still other direct functions of VEGF include enhanced glucose transport and induction of other vascular factors, including tissue plasminogen activator,14 urokinase-type plasminogen activator,15 and von Willebrand factor.11 VEGF also indirectly contributes to angiogenesis by inducing expression of other genes within the endothelial cell. Attachment of VEGF to its own receptor on the endothelial cell causes an increase in the expression of the alpha v beta 3 integrin receptor. This integrin receptor is upregulated in the endothelial cells of newly formed blood vessels in healing wounds and in the chorioallantoic membrane of the chick. 16 The production of VEGF, and that of its receptors on target cells, is induced by an insufficient vascular supply and the resultant reduction in tissue oxygen tension.17 Under normal conditions, the half-life of the protein is approximately 30 to 45 minutes, but this increases to 6 to 8 hours during periods of hypoxia. 18 In the present study, notable differences between the three study groups were encountered. Blood flow measurements based on dye fluorescence recordings varied significantly from group to group, but did not accurately predict ultimate flap survival. More importantly, there was a significant difference in the ultimate viability of the flaps. Flaps that received VEGF cDNA before pedicle ligation had markedly improved tissue survival. The noticeable declines seen in both parameters of the vector-treated animals may be attributed to the harmful, and potentially thrombogenic, manipulation of the pedicle without the addition of beneficial gene therapy.
Differences between the experimental groups were also noted when the tissues were examined under the light microscope. In those animals that received the VEGF gene, the subcutaneous tissue supplying the flap contained a greater number of total blood vessels, and a larger proportion of smaller blood vessels. These smaller blood vessels likely represent younger vessels that formed in response to VEGF stimulation. Similar results were not noted with those animals that received either saline or the vector alone.
Immunohistochemical staining for VEGF using antibodies directed against the protein confirmed production of the protein in the healing tissues. The amount of protein noted in each group of specimens could be quantified by the intensity of the antigen-antibody complex deposition and staining. Complex deposition was most pronounced in tissues that received the gene for VEGF and were later subjected to an ischemic insult. Specimens harvested from the nonoperated side of the abdomen in the gene-treated group had significantly less intense staining; it was similar to that of the operated and nonoperated saline-treated specimens.
The results were duplicated by a second blinded observer who also examined the slides and graded the intensity of the staining. The absence of profound staining in nonoperated specimens indicated that VEGF cDNA had little systemic effect when the clamps were released after infusion of the solution. The operated specimens in the saline-treated group represented the baseline response to ischemia in nonmanipulated, ischemic tissues. The results demonstrated that treatment of the flaps with VEGF cDNA can accentuate the cellular response to ischemia by producing increased amounts of VEGF as a means of augmenting the production of nutrient blood vessels which, in turn, increases the viability of the vascularized tissue.
One explanation for the results obtained might be that injection of foreign material into the vessel caused thrombosis of the pedicle. As a result of the thrombosis, angiogenesis might have been stimulated independent of the action of VEGF. This interpretation, however, was refuted by two findings. One, there was a significant difference in the viability of flaps that received vector alone and vector with VEGF, even though the two solutions differed only by a small segment of genetic material. Second, on inspection of the flaps before death, none of the surviving flaps had a demonstrable clot in the pedicle.
Summary
The current findings suggest that local intraarterial infusion of cDNA encoding VEGF is capable of improving the survival of ischemic skin flaps. They offer evidence that gene therapy may be an effective means of modulating the body's response to tissue injury and improve wound healing. Future investigations based on this work will use the techniques of gene therapy to determine the optimal delivery medium, to establish the amount of time necessary for the development of adequate collateral circulation, and to increase the area supplied by any given single vascular pedicle. 
